Cite
Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper.
MLA
Ibrahim, Nasrien E., et al. “Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper.” JACC. Heart Failure, vol. 8, no. 5, May 2020, pp. 347–58. EBSCOhost, https://doi.org/10.1016/j.jchf.2019.12.010.
APA
Ibrahim, N. E., Burnett, J. C., Jr, Butler, J., Camacho, A., Felker, G. M., Fiuzat, M., O’Connor, C., Solomon, S. D., Vaduganathan, M., Zile, M. R., & Januzzi, J. L., Jr. (2020). Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper. JACC. Heart Failure, 8(5), 347–358. https://doi.org/10.1016/j.jchf.2019.12.010
Chicago
Ibrahim, Nasrien E, John C Burnett Jr, Javed Butler, Alexander Camacho, G Michael Felker, Mona Fiuzat, Christopher O’Connor, et al. 2020. “Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper.” JACC. Heart Failure 8 (5): 347–58. doi:10.1016/j.jchf.2019.12.010.